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In vivo efficacy of human immunodeficiency virus neutralizing
antibodies: estimates for protective titers
Abstract
The definition of plasma neutralizing antibody titers capable of controlling human immunodeficiency
virus (HIV) infection in vivo is considered a critical step in vaccine development. Here we provide
estimates for effective neutralization titers by assessing samples from a recent passive immunization
trial with the neutralizing monoclonal antibodies (MAbs) 2G12, 2F5, and 4E10 using an analytic
strategy that dissects the contributions of these MAbs to the total neutralization activity in patient
plasma. Assessment of neutralization activities for six responding patients with partial or complete
control of viremia during the MAb treatment and for the eight nonresponding patients revealed a
significant difference between these groups: Among responders, MAb-mediated activity exceeded the
autologous neutralization response by 1 to 2 log units (median difference, 43.3-fold), while in the
nonresponder group, the autologous activity prevailed (median difference, 0.63-fold). In order to reach a
50% proportion of the responders in our study cohort, MAb neutralizing titers higher than 1:200 were
required based on this analysis. The disease stage appears to have a significant impact on the quantities
needed, since titers above 1:1,000 were needed to reach the same effect in chronic infection. Although
our analysis is based on very small sample numbers and thus cannot be conclusive, our data provide a
first estimate on how in vitro-measured neutralizing antibody activity can relate to in vivo efficacy in
controlling HIV infection and may therefore provide valuable information for vaccine development.
Interestingly, lower neutralizing antibody levels showed an effect in acute compared to chronic
infection, suggesting that in early disease stages, therapeutic vaccination may show promise. Equally,
this raises hopes that a preventive vaccine could become effective at comparatively lower neutralizing
antibody titers.
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The definition of plasma neutralizing antibody titers capable of controlling human immunodeficiency virus
(HIV) infection in vivo is considered a critical step in vaccine development. Here we provide estimates for
effective neutralization titers by assessing samples from a recent passive immunization trial with the neutral-
izing monoclonal antibodies (MAbs) 2G12, 2F5, and 4E10 using an analytic strategy that dissects the contri-
butions of these MAbs to the total neutralization activity in patient plasma. Assessment of neutralization
activities for six responding patients with partial or complete control of viremia during the MAb treatment and
for the eight nonresponding patients revealed a significant difference between these groups: Among responders,
MAb-mediated activity exceeded the autologous neutralization response by 1 to 2 log units (median difference,
43.3-fold), while in the nonresponder group, the autologous activity prevailed (median difference, 0.63-fold). In
order to reach a 50% proportion of the responders in our study cohort, MAb neutralizing titers higher than
1:200 were required based on this analysis. The disease stage appears to have a significant impact on the
quantities needed, since titers above 1:1,000 were needed to reach the same effect in chronic infection. Although
our analysis is based on very small sample numbers and thus cannot be conclusive, our data provide a first
estimate on how in vitro-measured neutralizing antibody activity can relate to in vivo efficacy in controlling HIV
infection and may therefore provide valuable information for vaccine development. Interestingly, lower neu-
tralizing antibody levels showed an effect in acute compared to chronic infection, suggesting that in early
disease stages, therapeutic vaccination may show promise. Equally, this raises hopes that a preventive vaccine
could become effective at comparatively lower neutralizing antibody titers.
Human immunodeficiency virus (HIV) vaccine development
faces many obstacles. Most importantly, the type and quantity
of immune responses required for protection have not been
completely unraveled. The perception that both humoral and
cellular immune responses to HIV are essential for successful
viral defense receives wide acceptance (5, 13, 17). The speci-
ficities of protective antibody and cellular responses, however,
remain to be defined, as does the magnitude of these re-
sponses. The latter poses a particular conundrum for HIV
vaccine design, because efficacy analysis of vaccine candidates
must be based largely on preclinical assessment and studies
with animal models. Methods that allow data from in vitro
analysis of vaccine responses to be related to their in vivo
impacts are thus urgently needed. In the present study, we
aimed to obtain an estimate for protective neutralization titers
(NTs) in vivo by using samples from a recent passive immuni-
zation trial with the neutralizing antibodies 2G12, 2F5, and
4E10 (26). Through in-depth analyses of the activities of the
monoclonal antibodies (MAbs) in vitro and in patient plasma
samples analyzed ex vivo and of their observed in vivo effects,
we were able to obtain estimates for in vivo active NTs that
could provide guidance for future vaccine studies.
MATERIALS AND METHODS
Clinical specimens. Patient plasma and virus isolates utilized in this study were
obtained during a passive immunization trial recently conducted as described
elsewhere (26). Written informed consent was obtained from all 14 individuals
enrolled according to the guidelines of the ethics committee of the University
Hospital Zurich. The patient demographics and clinical setup have been pub-
lished previously (26). A brief summary of the patient specificities indicating
disease stage (acute/chronic) and response to the passive immunization treat-
ment is provided in Table 1. Prior to participation in the passive immunization
trial, acutely and chronically infected patients had to be on successful antiretro-
viral therapy (viral load  50 RNA copies/ml) for at least 6 months and 3
months, respectively (26). Patients were stratified into responders and nonre-
sponders as defined previously (26) by classifying those with delayed viral re-
bound or complete suppression of viremia during the trial as responders and the
remaining patients as nonresponders.
Antibodies and cell lines. MAbs 2G12, 2F5, and 4E10 (21, 25, 27, 30) were
produced by recombinant expression in CHO cells as immunoglobulin G1() as
described previously (1, 24). TZM-bl cells (National Institutes of Health AIDS
Research and Reference Reagent Program) (28) and 293T cells were cultivated
in Dulbecco’s modified Eagle medium containing 10% fetal calf serum.
Full-length-envelope cloning. The cloning and sequencing of functional viral
envelope genes of these patient isolates have been described previously (10).
One to three functional envelope clones of each isolate were used to generate
Env-pseudotyped HIV particles as described elsewhere (8, 10, 28).
Generation of envelope-pseudotyped HIV particles. Briefly, 293T cells were
transfected with plasmids carrying the reporter gene expressing the virus back-
bone, pNLluc-AM (20) (a kind gift from A. Marozsan and J. P. Moore), and the
functional envelope clone at a ratio of 3:1 by using polyethylenimine (linear 25
kDa; Polysciences) as described elsewhere (10). Viral supernatants were har-
vested 2 days posttransfection and infectivity determined as described elsewhere
(6). To this end, TZM-bl cells were infected with viral supernatants in Dulbecco’s
modified Eagle medium, 10% heat-inactivated fetal calf serum, and 1% penicil-
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lin-streptomycin (BioWhittaker) containing 10 g/ml DEAE dextran (Amer-
sham Biosciences).
Neutralization assays with Env-pseudotyped reporter gene viruses. Neutral-
ization activities of MAbs and patient plasma against pseudotyped virus were
evaluated on TZM-bl cells essentially as described elsewhere (14). Heat-
inactivated plasma samples were centrifuged (10,000  g) and probed at
serial dilutions starting at 1:40. One hundred to 200 50% tissue culture
infective doses (TCID50) of the virus were preincubated with serial dilutions
of plasma or antibody for 1 h before the infection mixture was transferred to
TZM-bl cells. The antibody concentration or plasma dilution causing a 70%
reduction in luciferase reporter gene production after 48 h was determined by
regression analysis. Two to three independent experiments were performed
for each individual envelope clone. Inhibitory doses for a specific patient are
presented as means of the values derived against the individual clones. The
cutoff in the neutralization assay was a titer of 1:40. For statistical evaluation
samples that did not reach 70% neutralization at this dilution, a titer of 1:40
was used.
Pharamacokinetic analyses of 2F5, 4E10, and 2G12 concentrations in plasma.
Plasma 2F5, 4E10, and 2G12 concentrations were quantified previously using
established 2F5-, 4E10-, and 2G12-specific double-sandwich enzyme-linked
immunosorbent assays (ELISA) (limit of detection, 3 ng/ml) (1, 7, 24, 26).
Mean trough (preinfusion) MAb concentrations between weeks 2 and 12 were
determined for each patient except for patients NAB13 and -14, for whom
week 2 samples were not available and analysis was restricted to weeks 4 to
12 (Table 1).
Determination of synergy in antibody neutralization. Based on the MAb
concentrations determined in plasma for each individual patient and the
relative ratios of the three MAbs to each other (Table 1), we assessed the
effects of combinations of the MAbs on the inhibition of the patients’ viruses
by using corresponding Env-pseudotyped viruses with TZM-bl cells and de-
termining the interaction indices (Inx) according to the method of Loewe (2,
3, 9) (Table 1).
Analytic strategy used to dissect neutralization activities in patient sera. An
overview of the strategy used to dissect the neutralization activity is provided in
Table 2. As outlined there, MAb doses in plasma (DPlasma
MAb ) were first determined
by ELISA, and mean trough concentrations between weeks 2 and 12 were
calculated. Then the inhibitory activity of each MAb against the isolate was
measured in the TZM-bl assay in vitro, and the individual 70% inhibitory con-
centrations (IC70s) were determined. Combination effects were assessed via Inx
of the MAbs active against the respective patient-specific virus isolate in the
TZM-bl assay using a mixture of the MAbs at fixed ratios derived from their
mean in vivo concentrations (DPlasma
MAb ) (Table 2). If a MAb by itself did not reach
an inhibitory activity at concentrations of 50 g/ml against a specific virus, it
was not included in the determination of the Inx against this isolate. We decided
on this approach because we found that these MAbs generally do not act
antagonistically. Hence, leaving out measurements where IC70 NTs were not
achieved is a more conservative approach, since it reduces the chances of over-
estimating synergy according to formula 4 (Table 2).
The expected 70% MAb NTs (NT70
MAb) were then calculated from their respec-
tive inhibitory doses and Inx and the measured plasma MAb level using the
formula given for analysis 5 in Table 2. Total plasma neutralization activity
(NT70
total), which consists of plasma antibody- and MAb-mediated activities, was
determined experimentally in the TZM-bl assay by assessing the reciprocal 70%
inhibitory titers in patient plasma against the corresponding virus throughout the
trial. From these data, autologous plasma neutralization activity (NT70
aut) was
deduced by subtracting the MAb-mediated NT from the respective total NT
(analysis 7). In cases where NT70
MAbwas NT70
total, a lower cutoff of 10 was used for
NT70
aut. Data used for statistical analysis are means of NTs measured between
weeks 2 and 12.
Data analysis. Data analyses were performed using Prism, version 4.03 for Win-
dows (GraphPad Software, San Diego, CA) and Stata SE, version 10 for Windows
(Stata Corporation, College Station, TX). Nonparametric methods were employed
for testing of group differences (the Mann-Whitney U test for unpaired comparisons
and the Wilcoxon signed-rank test for paired comparisons). Linear regression with
robust standard errors to account for the potential clustering of data points from the
same individual was used for assessing the relationship between total NTs and MAb
titers. All tests of significance were two-tailed, and the level of significance was set at
0.05. No adjustments for multiple testing were made.
Nucleotide sequence accession numbers. The clonal envelope sequences gen-
erated in this study have been deposited in the GenBank database (http://www
.ncbi.nlm.nih.gov/GenBank/index.html) (10). The assigned accession numbers
are as follows: for NAB1pre-cl_12, EU023916; for NAB1pre-cl_30, EU023917;
for NAB1pre-cl_39x, EU023918; for NAB2pre-cl_3, EU023919; for NAB3pre-
cl_7, EU023920; for NAB3pre-cl_43, EU023921; for NAB4pre-cl_1, EU023922;
for NAB5pre-cl_1, EU023923; for NAB6pre-cl_8, EU023924; for NAB6pre-
cl_11, EU023925; for NAB7pre-cl_20, EU023926; for NAB8pre-cl_11,
EU023927; for NAB9pre-cl_106, EU023928; for NAB10pre-cl_2, EU023929; for
NAB10pre-cl_11, EU023930; for NAB11pre-cl_11, EU023931; for NAB11pre-
cl_18, EU023932; for NAB12pre-cl_7, EU023933; for NAB12pre-cl_10,
EU023934; for NAB12pre-cl_12, EU023935; for NAb13pre-cl_1, EU023936;
for NAB13pre-cl_9, EU023937; for NAB14pre-cl_15, EU023938; and for
NAB14pre-cl_7, EU023939.
TABLE 1. Ex vivo and in vitro analysis of neutralization activitya
Patient Stage Response
IC70 (g/ml) of:
Mean DPlasma (g/ml), wk
2–12)b Synergy analysis
NT70 of plasma against:
JR-FL Autologousvirus
2G12 2F5 4E10 2G12 2F5 4E10 MAb ratioc Inx70d Total MAb Total MAb
NAB01 C No 50 1.6 0.8 406.1 85.7 144.1 20:4:7 0.734 227 241 1,125 525
NAB02 C No 21.3 2.2 3.1 376.8 50.7 85.7 8:1:2 0.380 375 279 281 137
NAB03 C Yes 0.6 7.0 7.9 523.9 48.4 115.1 10:1:2.5 0.676 394 490 1,022 1,691
NAB04 C Yes 3.2 0.5 1.7 640.7 97.0 161.1 14:2:3 0.554 491 539 1,109 1,349
NAB05 C No 50 7.2 14.4 232.7 18.9 37.8 12:1:2 0.621 348 285 112 9
NAB06 C No 17.7 8.9 9.0 281.9 60.3 72.4 10:2:2.5 0.507 878 348 273 76
NAB07 C No 50 50 9.3 463.4 46.0 98.0 10:1:2 1.000 548 624 196 11
NAB08 A Yes 5.8 3.7 5.0 554.5 62.7 108.8 10:1:2 0.524 511 623 308 259
NAB09 C No 50 1.8 14.0 271.6 47.4 70.3 7:1:1.5 0.769 319 233 2,814 58
NAB10 A No 50 5.0 13.4 670.3 65.3 180.3 10:1:3 0.634 786 578 181 114
NAB11 A No 14.3 10.5 14.8 649.4 58.6 128.2 12:1:2.5 0.575 334 526 49 162
NAB12 A Yes 9.7 50 20.0 484.4 74.6 142.3 8:1:2 0.608 513 461 42 125
NAB13e A Yes 50 0.2 12.8 726.2 92.7 175.7 8:1:2 1.082 351 475 443 742
NAB14e A Yes 50 0.3 1.7 752.2 80.6 189.8 10:1:2.5 0.927 592 612 2,508 486
a A, acute HIV infection; C, chronic HIV infection. Response to passive immunization was assessed as described previously (26). IC70s of MAbs against the respective
pretreatment patient viruses and mean total or MAb-mediated NT70s of patient plasma samples against JR-FL or autologous viruses were measured in the TZM-bl
assay system.
b Mean trough dose of MAb in plasma samples of patients during weeks 2 to 12 of passive immunization (see Trkola et al. 26).
c Averaged MAb ratio (2G12:2F5:4E10) chosen for synergy analysis.
d Inx at 70% inhibition, calculated as shown in Table 2. Inx70 was calculated only for MAbs with IC70s of 50 g/ml.
e Week 2 sample unavailable; analysis restricted to samples from weeks 4 to 12.
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RESULTS
Dissecting the contribution of MAbs and autologous anti-
bodies to neutralization activity ex vivo. The first aim of our
study was to define if and to what extent the passively trans-
ferred MAbs 2G12, 2F5, and 4E10 can contribute to the neu-
tralization activity in patient plasma. Using samples from a
recently conducted passive immunization trial with these
MAbs (7, 26), we first assessed the activities of the MAbs and
patients’ plasma antibodies against the heterologous virus JR-
FL. For this analysis, a neutralization assay system based on
the infection of the genetically engineered reporter cell line
TZM-bl with an envelope-pseudotyped reporter gene virus was
chosen; owing to its robustness, sensitivity, and high reproduc-
ibility, this assay allows for a detailed mathematical analysis (8,
23, 28). To derive information on the individual contributions
of the MAbs and the autologous patient antibodies, we estab-
lished an iterative analysis strategy that took into account the
individual MAb concentration in patient plasma, the sensitivity
of the viral strain to the MAbs alone and in combination, and
potential synergistic and antagonistic effects (Table 1). Using
this strategy (outlined in detail in Table 2 and Materials and
Methods), we were able to define the theoretical contributions
of the MAbs to the overall neutralization activity and, in turn,
the autologous neutralization activity during the passive im-
munization period.
Passively transferred MAbs 2G12, 2F5, and 4E10 are active
in patient plasma. We first assessed neutralization activity in
patient plasma against the heterologous virus JR-FL in order
to determine if any of the MAbs were active in patient plasma
during passive immunization and, if so, which of the three
MAbs were active. Longitudinal plasma samples collected be-
fore passive immunization (pretreatment time point), during
treatment (preimmunization time points at weeks 2, 4, 6, 8, 10,
and 12), and during the follow-up period (weeks 14, 16, 18, 20,
22, and 24) were analyzed for neutralization activity (Fig. 1A).
Activities against JR-FL before and after passive immunization
were markedly lower for all patients than the activities mea-
sured during MAb treatment, indicating that the MAbs were
active in the patient plasma (Fig. 1A and B; Table 3, analyses
I and II). Altogether, the examination of the neutralization
activity against JR-FL provided further evidence that all three
MAbs retained their neutralization capacities in patient
plasma and contributed to the MAb-induced inhibitory activity
in plasma, confirming that no interference with binding to
cellular proteins in plasma occurred.
In agreement with our previous analyses (7, 10, 26), we found
that 2G12 was the most potent of the three MAbs, reflecting the
higher plasma concentrations 2G12 achieved (Fig. 2A; Table 3,
analyses V and VI). The cross-neutralization activity measured in
total plasma against the heterologous strain JR-FL associated to
similar extents with the calculated MAb-mediated activity in re-
sponding and in nonresponding patients (Fig. 2B), also suggesting
that the MAbs might have an impact on in vivo neutralization
activity. Nonetheless, neither the total neutralization activity in
plasma measured against the heterologous strain JR-FL nor the
MAb-induced activity against this virus was indicative of a pa-
tient’s response to the passive immunization treatment (Table 3,
analyses III and VII).
Evaluating the contributions of MAbs and plasma antibody
to inhibition of the autologous patient virus. In order to eval-
uate the MAb responses against the patient’s autologous iso-
lates, we cloned the envelope genes from all 14 patient viruses
before the start of passive immunization therapy. All derived
replication-competent envelope genes used for this analysis
TABLE 2. Analytic strategy used to dissect MAb and autologous neutralization activities in patient plasma
Analysis Description Analysis type Formula/symbols
1 Trough MAb dose in plasma
(DPlasma
MAb )
ELISA, ex vivo analysis of plasma
samples
DPlasma
2G12 or DPlasma
2F5 or DPlasma
4E10
2 Inhibitory dose of MAb against
the isolate in vitro (IC70
MAb)
TZM-bl neutralization assay, in
vitro analysis of MAbs against
viruses; IC70
MAb (g/ml)
determined by linear regression
IC70
2G12 or IC70
2F5 or IC70
4E10
3 Inhibitory doses of the MAbs in
combination at fixed ratios of
MAbs reflecting in vivo
concentrations against the
isolate in vitro (IC70
MAb(mix))
TZM-bl neutralization assay, in
vitro analysis of MAb
combinations against viruses;
IC70
MAb(mix) (g/ml) determined
by linear regression
IC70
2G12(mix) or IC70
2F5(mix) or IC70
4E10(mix)
4 Combination effects of the MAbs Inx determined according to the Inx70 	 IC70
2G12(mix)/IC70
2G12  IC70
2F5(mix)/IC70
2F5
were assessed as interaction method of Loewe at 70%  IC70
4E10(mix)/IC70
4E10
indices (Inx) according to the inhibition in TZM-bl
work of Loewe (9) using fixed neutralization assay in vitro
ratios of MAbs reflecting in
vivo concentrations
5 Calculate expected MAb NTs NT70
2G12, NT70
2F5, and NT70
4E10 NT70
MAb 	 (1/Inx70) · (DPlasma
2G12 /IC70
2G12  DPlasma
2F5 /IC70
2F5
calculated from corresponding  DPlasma
4E10 /IC70
4E10)
inhibitory doses, Inx70, and the
measured plasma MAb level
6 Total plasma neutralization
activity (NT70
total)
Ex vivo analysis of patient plasma
in TZM-bl neutralization assay;
reciprocal titer (NT70
total)
determined by linear regression
NT70
total
7 Autologous plasma neutralization
activity (NT70
aut)
Calculation NT70
aut  NT70
total  NT70
MAb
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were sequenced to verify that they were representative for the
individual patients (see Materials and Methods) (10). In most
cases we found good agreement between the sensitivities of the
isolates that had been determined previously using a periph-
eral blood mononuclear cell-based assay system (10, 26) and
the inhibitory activities of the MAbs against the cloned Env-
pseudotyped viruses in the TZM-bl assay (Table 1). The virus
from patient NAB14 was known to be insensitive to 2G12 (10,
26). Notably though, 6 out of the 13 prestudy viruses that were
inhibited by 2G12 at relatively high doses in the peripheral
blood mononuclear cell assay were not inhibited by 2G12 at
concentrations below 50 g/ml in the TZM-bl assay (Table 1)
(10). Equally, 2F5 at 50 g/ml did not effect 50% inhibition of
two isolates (from NAB07 and NAB12) in the TZM-bl assay.
In all these cases, mutations within the core epitopes of the
MAbs were present both in the original virus isolate and in the
cloned envelope, suggesting that the TZM-bl system is more
prone to detect such epitope mismatches (10, 26; P. Rusert et
FIG. 1. Dissection of MAb contributions to neutralization activity. Total, MAb-mediated, and patients’ (autologous) antibody (Ab)-mediated
neutralization activities (70% NT) against the heterologous virus JR-FL (A and B) and the autologous viruses (C and D) were evaluated for all 14
patients. Data are means from two to four independent experiments. (A and C) Representative profiles of neutralization activities of plasma from patient
NAB04 against JR-FL (A) and the autologous virus of patient NAB04 (C), analyzed throughout the trial. The MAb infusion period and off-treatment
phase (MAb washout) are indicated. Gray squares, viral load (VL; expressed as copies of HIV RNA/ml of patient plasma); black circles with solid lines,
total neutralization activity in plasma (combined autologous-Ab and MAb activities); dashed lines, autologous-Ab activity. The calculated MAb NTs are
shown in separate panels as dark red, orange, and green areas for 2G12, 2F5, and 4E10, respectively. The sum of the activities of all three MAbs is shown
as a light blue area in the top panel. (B and D) Summary of total neutralization activity (black) and MAb-mediated neutralization activity (red) for each
of the 14 individuals during the trial against JR-FL (B) and autologous viruses (D).
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al., unpublished data). Nevertheless, we observed trends sim-
ilar to those described in our initial studies, which indicated a
higher neutralization activity of 2G12, but not of 2F5 or 4E10,
among responding patients (Fig. 2A and C). Total plasma
neutralization activity (consisting of the activities of autologous
plasma antibody and passively administered MAbs) against the
autologous virus before, during, and after passive immuniza-
tion was defined as described above. This activity differed sub-
stantially among patients (Fig. 1C and D). As expected, the
autologous neutralization activity was markedly higher in
chronic than in acute infection at the pretreatment time point
but was also increased in acutely HIV infected individuals with
resuming viral replication (Table 3, analyses IX and X). At the
completion of the trial, no significant difference in neutraliza-
tion activity between acute and chronic infection was observed
(Table 3, analysis X). We noted a wider range for the neutral-
ization activity mediated by the triple MAb combination in
plasma against the patients’ autologous viruses (NT70 range, 7
to 2,025 [Fig. 1D]) than for the activity measured against the
heterologous virus JR-FL (NT70 range, 190 to 946 [Fig. 1B]).
The latter was to be expected, since heterologous neutraliza-
tion activity is notoriously low in HIV infection, and therefore
the inhibitory activity against JR-FL depends predominantly
on MAb levels in patient plasma, while the autologous plasma
antibodies, the MAb doses, and the sensitivity of the specific
viral strain to the MAbs influence the NT against the autolo-
gous virus. Dissection of the homologous activity (plasma an-
tibody- and MAb-mediated inhibition of the autologous virus)
indicated that all three MAbs were active against these patient
viruses and contributed to the total plasma neutralization ac-
tivity (Fig. 2C). Of note, for five patients (NAB03, NAB04,
NAB11, NAB12, and NAB13), the predicted MAb neutraliza-
tion activity was higher than the observed total neutralization
activity. The cause of this discrepancy is not clear, because we
were unable to detect antagonistic effects between antibodies
in patient plasma and the three MAbs (data not shown). How-
ever, overall we observed a high degree of association between
MAb-mediated activity and total neutralization activity in re-
sponders but not in nonresponding patients, underlining fur-
ther that among nonresponders the MAbs had a low impact on
the neutralization activity (Fig. 2D).
Effect analysis. Side-by-side comparison of the neutraliza-
tion activity of the autologous antibody response and the MAb-
mediated activity against each patient’s isolate (Fig. 3A) re-
vealed a marked difference between the patient groups: With
one exception (NAB14), MAb activity exceeded the patients’
autologous antibody NTs in responding patients, while in non-
responders the autologous activity was dominant. To what ex-
tent the viremia control of patient NAB14, who controlled
viremia to undetectable levels up to the last available sampling
TABLE 3. Group comparisons of measured parametersa
Parameter Analysis Unit of analysis
Subgroup 1 Subgroup 2
Test P
Subgroup name n Median IQR Subgroup name n Median IQR
Total plasma
NT70
I Heterologous
virus NT70
Pretreatment 14 40 40–84 Wk 12 14 482 342–578 W 0.0001
(NT70
total) II Heterologous
virus NT70
Wk 12 13b 436 342–551 Wk 24 13 113 55–154 W 0.0046
III Heterologous
virus NT70
Responders 6 501 373–553 Nonresponders 8 361 327–667 M 0.491
IV Autologous virus
NT70
Responders 6 732 175–1,808 Nonresponders 8 234 147–703 M 0.414
MAb NT70
(NT70
MAb)
V Heterologous
virus NT70
NT70
2G12 14 350 205–455 NT70
2F5 14 78 40–122 M 0.0001
VI Heterologous
virus NT70
NT70
2G12 14 350 205–455 NT70
4E10 14 30 18–44 M 0.0001
VII Heterologous
virus NT70
Responders 6 514 468–618 Nonresponders 8 317 260–552 M 0.181
VIII Autologous virus
NT70
Responders 6 614 192–1,520 Nonresponders 8 95 35–149 M 0.0127
IX Autologous virus
NT70;
pretreatment
Acute 6 40 40–40 Chronic 8 110 93–243 NAc
X Autologous virus
NT70; wk 24
Acute 6 168 51–455 Chronic 7 178 160–2,062 M 0.366
Autologous-
Ab NT70
(NT70
aut)
XI Autologous virus
NT70
Responders 6 10 10–1,036 Nonresponders 8 165 85–399 M 0.0813
Fold XII NT70
MAb/NT70
aut Responders 6 43.3 2.74–152 Nonresponders 8 0.63 0.07–16.2 M 0.0293
difference XIII NT70
MAb/NT70
aut Responders without
NAB14d
5 74.2 8.9–152 Nonresponders 8 0.63 0.07–16.2 M 0.0062
a IQR, interquartile range; W, Wilcoxon signed rank test; M, Mann-Whitney U test; NA, not applicable; Ab, antibody.
b Patient NAB06 reinititated antiretroviral therapy after week 12; thus, data from only 13 patients are available for group comparison of weeks 12 and 24.
c Group comparison not applicable, because at the pretreatment time point, no neutralization activity was detectable in acute infection; the NT range for chronic
infection was 71 to 965.
d Patient NAB14 was excluded from the analysis.
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time point (2 years of follow-up), was mediated by monoclonal
or autologous antibody activity cannot be assessed conclu-
sively. For the other five responders, MAb NTs exceeded au-
tologous-antibody titers by approximately 1 to 2 log units (Fig.
3C; Table 3, analyses XII and XIII). Of particular interest, the
MAb-mediated neutralization activity was significantly higher
in responders, whereas no difference in total or autologous
neutralization activity was observed between the patient
groups, thus confirming the influence of the MAb treatment on
the trial outcome (Fig. 3B; Table 3, analyses VIII, IV, and XI).
We found no association with treatment success when we an-
alyzed total or autologous neutralization activity. Overall, the
result of this investigation was strikingly explicit: in general,
responses to passive immunization were observed for those
individuals for whom the activity of the MAb exceeded the
patient’s own neutralization response.
Prediction of protective in vivo titers. The main and final
intent of the present study was to define ex vivo plasma NTs of
the MAbs that show in vivo impact. With this we hoped to
derive directives on the magnitude of plasma NTs that must be
evoked by successful vaccines. To address this, we employed
the method of Reed and Muench (15, 22) (Fig. 4A), which
allowed us to estimate NTs required to initiate response or to
reach a specific proportion of responding patients (e.g., 50 or
100%). In our cohort, response minimally required a MAb-
mediated NT of 1:100 (NT70
MAbof the responder with the low-
est activity). To achieve a 50% proportion of all responders,
the MAb-mediated NTs had to be above 1:200 (Fig. 4A).
Above an NT70
MAbof 525, all patients were responders. Notably,
when patients were stratified into acute- and chronic-phase
patients, it became evident that considerably higher MAb NTs
were required for protection in chronic infection (NT, 1,000)
than in acute infection (NT, 200) to achieve the 50% pro-
portion of responders (Fig. 4B).
DISCUSSION
HIV vaccine development has to overcome a multitude of
hurdles, including the definition of the type and quantity of
cellular and humoral responses required for protection (5, 13,
FIG. 2. Dissection of MAb contribution to neutralization activity. (A and C) Comparison of mean MAb-mediated NT70s between weeks 2 and
12 for nonresponding and responding patients against the heterologous virus JR-FL (A) and the autologous viruses (C). Dark red, orange, and
green bars represent 2G12-, 2F5-, and 4E10-mediated activities, respectively. Cumulative MAb NTs (sum of all three MAb NTs) (blue bars) for
each patient were used to compare the effects of MAb neutralization in responders and nonresponders. Median (interquartile range [IQR]) MAb
NTs and P values by the Mann-Whitney U test are provided. (B and D) Simple linear regression analysis of interdependency between total and
MAb-mediated neutralization activities against the heterologous virus JR-FL (B) and autologous viruses (D) using robust methods of variance
estimation to adjust for intrapatient clustering of measurements. For regression model output and measures of goodness of fit, see insets. Note
that confidence intervals (CI) not encompassing zero indicate statistically significant slopes. Black and red symbols represent nonresponders and
responders, respectively. Data are means from two to four independent experiments.
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17). The failure to create vaccines based on humoral immunity,
despite concentrated efforts over the past 2 decades, has made
obvious that vaccination strategies that can elicit potent HIV
neutralizing antibody responses will require not only new con-
cepts in immunogen design but also the installment of appro-
priate assay systems that allow, at the preclinical stage, assess-
ment of the induced responses and their potential in vivo
impacts (8, 23, 28). In the present study, we focused on the
FIG. 3. Influence of MAb-mediated neutralization activity on treatment outcome. Shown are analyses of mean NTs between weeks 2 and 12.
(A) Cumulative MAb NT70s (orange bars) and autologous neutralization activity (green bars) against autologous viruses in nonresponders and
responders. (B) Comparison of total (black), autologous-antibody-mediated (green), and MAb-mediated (orange) NT70s against autologous
viruses in nonresponding (open symbols) and responding (solid symbols) patients. Group comparisons were performed using the Mann-Whitney
test. (C) Ratio of MAb-induced responses to autologous responses in responding (solid circles) versus nonresponding (open circles) patients.
Group comparisons were performed using the Mann-Whitney test.
FIG. 4. Prediction of MAb NTs required for protection. (A) Estimated MAb NTs against the autologous viruses required to achieve 50%
protection among responding patients according to the method of Reed and Muench (15, 22). The gray shaded area represents the threshold of
MAb NT activity required to achieve a 50% proportion of responders. (B) Analysis as described for panel A of a patient cohort subgrouped into
acute and chronic individuals. Blue and green shaded areas represent the thresholds of MAb NT activity required to achieve a 50% proportion
of responders among acute and chronic individuals, respectively.
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latter topic. By performing a retrospective analysis of NTs in
plasma evoked by passive immunization with the neutralizing
MAbs 2G12, 2F5, and 4E10 (26), we aimed to define in vitro
plasma NTs that were associated with in vivo effects. Samples
from 14 patients who participated in the passive immunization
trial with the three MAbs were available for this analysis. As
outlined, we defined the theoretical contributions of the MAbs
to the overall neutralization activity in patient plasma by taking
into consideration MAb concentrations, the sensitivities of the
viral strains to the MAbs, synergistic and antagonistic effects,
and autologous-antibody activity. The highly standardizable
neutralization assay system employing Env-pseudotyped re-
porter gene viruses on TZM-bl cells is recommended for as-
sessment of vaccine responses, due to its robustness and low
inter- and intralaboratory variation (8, 11). Use of this system
allowed us to perform an in-depth analysis combining experi-
mental and arithmetic approaches. Deriving the theoretical
neutralization activity of the passively administered MAbs dur-
ing the trial enabled us to relate their in vitro neutralization
activities in patient plasma to the in vivo effects recorded for
the same individuals. The latter analysis provided a strikingly
clear result: Generally, irrespective of the disease stage, MAb-
induced activity had to exceed the patient’s own antibody ac-
tivity by 1 to 2 log units in order to show an in vivo effect. More
specifically, in order to achieve a 50% proportion of the re-
sponders in our trial, we estimated that in vitro MAb NTs
(NT70s) of 1:200 were required. Notably, the two responding
patients with chronic infection had very low autologous neu-
tralization activity. Nevertheless, a distinct difference between
the acutely and chronically infected patients in the quantities
required for this response was evident: response in chronic
infection depended on MAb NTs of 1:1,000. Our analysis is
based on very small patient numbers and therefore has to be
interpreted with caution. Nevertheless, the estimates of pro-
tective titers we derived from this analysis are intriguing: While
during passive immunization high MAb doses had to be deliv-
ered in order to achieve such neutralization activities in patient
plasma, these titers are in a reasonable range compared to the
autologous neutralizing antibody responses that can be ob-
served in HIV infection using this assay system (8, 23, 28).
Provided that immunogens can be developed that match in
vivo responses, effective vaccines may thus come in reach.
Our clinical study was not specifically designed to evaluate
the origin of viral escape mutants that emerge upon MAb
treatment. It can be reasoned, however, that the greater viral
diversity in chronic infection and the ensuing greater pool of
viral variants that can give rise to escape mutations may have
led to the lower efficacy of the MAbs at this clinical stage.
Equally, chances that MAb-resistant viral variants already exist
and will be reactivated from latently infected cells are likely
higher in chronic infection. A lower frequency of latently in-
fected cells during acute infection may have further impacted
MAb activity, since the number of infected cells will influence
the viral burden upon treatment interruption (4, 29). Alto-
gether, the higher efficacy of the MAb intervention in acute
infection may bear several important practical implications for
vaccination. Since a lower antibody activity showed an effect
early in infection, therapeutic vaccination is more likely to
eventually become feasible in this setting. Extrapolating this
further, one could speculate that the relatively low virus quan-
tities encountered during transmission may require even less
active antibody to induce protection, and thus even lower NTs
might be effective in the setting of protective vaccination. Nishi-
mura et al. have suggested that NTs in plasma of 1:38 or
greater would confer almost complete protection against a
virus challenge of 75 TCID50 based on studies of simian/HIV
challenge in pig-tailed macaques (15), and similar plasma NTs
have been found to confer protection in other animal studies
(12, 16, 18, 19). Considerably more work will need to be done
to determine exactly how high the bar for neutralizing titers is
in the diverse treatment and intervention settings in human
infection. Our study provides a first estimate of the range of
NTs required for in vivo activity. However, these estimates
need to be carefully evaluated, since they are based on small
sample numbers. More data linking in vitro assessment and
clinical impact are needed to establish a greater degree of
accuracy in this matter. Nevertheless, our study leaves room
for cautious optimism with respect to the development of ef-
fective vaccines, because it provides evidence that the neutral-
ization response required for in vivo activity is within the range
of responses that can be mounted during natural infection.
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